Novartis corrects misleading Clozaril statement

摘要

Novartis Pharmaceuticals has issued a corrective statement at the request of the Medicines and Healthcare products Regulatory Agency following the voluntary withdrawal earlier this year of two promotional booklets for Clozaril (clozapine).Novartis has accepted that the overall message of the booklets - that benefits of monitoring the quality of materials throughout the manufacturing process.Using process analytical technology,any problems can be picked up as they arise and the information can be fed back into the manufacturing process.